Updated from 3:09 p.m. EST

Shares of

Martek Bioscience

(MATK)

were among the best-performing health and pharmaceutical stocks Friday, rising 14.7% after the company posted fourth-quarter results that beat expectations.

Excluding a one-time tax benefit, the company earned 33 cents a share on sales of $59.7 million. Analysts polled by Thomson First Call were expecting earnings of 30 cents a share on sales of $56 million. A year ago, the company earned 21 cents a share on sales of $38.6 million. Martek said the large sales increase was due to higher sales of nutritional products to its infant-formula licensees. Shares traded up $5.99 to $46.74.

Adeza Biomedical

(ADZA)

rose 23.1% on its first day of trading as a public company. The maker of women's health products sold 3.75 million shares at $16 apiece, raising $60 million. The pricing came in at the high end of its expected range of $14 to $16 a share. UBS Securities led the underwriting syndicate. Shares traded up $3.70 to $19.70.

Shares of

Advanced Neuromodulation Systems

(ANSI)

rose 2.7% after the company's spinal cord stimulation system received U.S. Food and Drug Administration marketing approval. ANS is currently building inventory to support a limited market test of its Genesis RC system, which will be followed by a broader launch, it said. Shares traded up $1.01 to $38.56.

Other health care volume movers included

Pfizer

(PFE) - Get Report

, down 28 cents to $27.09;

Guidant

(GDT)

, down $2.20 to $71.55;

Merck

(MRK) - Get Report

, up 1 cent to $28.74;

Johnson & Johnson

(JNJ) - Get Report

, down $1.06 to $60.25; and

Amgen

(AMGN) - Get Report

, down 38 cents to $63.95.